Compare Adaptive Biotechnologies Corp (ADPT) vs General Mills, Inc. (GIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs General Mills, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while General Mills, Inc. trades at $36.6 (market cap $19.80B). The key difference: General Mills, Inc. is far larger — about 5.9× Adaptive Biotechnologies Corp's market cap, and General Mills, Inc. pays a 6.58% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GIS | |
|---|---|---|
Market Cap | $3.33B | $19.80B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $51.84 |
52-Week Low | $10.24 | $32.17 |
Enterprise Value | $3.19B | $33.29B |
Dividend Yield | — | 6.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
General Mills (GIS) trades at $37.10, down 1.25% on the day, with a bullish technical signal from moving averages and a neutral RSI near 58. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025, while revenue has declined from $20.1B in 2023 to $19.5B in 2025. The company maintains a dividend of $0.61 per share and is implementing cost-saving initiatives targeting $3B by 2030 to counter margin pressures from private-label competition.
Outlook: GIS presents a value opportunity with a low P/E of 9.23, but faces headwinds from sluggish sales and negative net income margin. Risks include consumer spending shifts and high debt levels. Analyst consensus is cautious with a hold-heavy rating and a $36.14 price target slightly below current levels, suggesting limited near-term upside without stronger earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
